Oncology Data Advisor® · Staying Proactive in Management of Infusion-Related Reactions With Julianna Cebollero, PharmD, BCOP For patients receiving cancer treatment, infusion-related reactions pose a significant risk and management is complicated by the lack of standardized terminology and varying risk factors. At the 48th Annual Oncology Nursing Society (ONS) Congress, Julianna Cebollero, PharmD, BCOP, Hematology-Oncology Clinical Pharmacy Specialist at Grady Health System, sat down ...

A biosimilar is a biological agent that is very much like another previously FDA-approved biological agent, called the reference drug. Biosimilars and their reference drugs are both made from living organisms, but they may be made in different ways and of slightly different substances. A biosimilar must demonstrate the same safety and efficacy and work in the same way as the reference drug, and it must also be used in the same way, at the same dose, and for the same condition. There are currentl...

Biosimilars—a biologic that is "similar" to another biologic drug that is already FDA approved—are becoming more common to prescribe to patients with various conditions. It is crucial for health care providers to keep abreast of the current information regarding biosimilars. To help educate oncology nurses on this emerging field, Eric Zack, DNP, RN, ACNP-BC, AOCN®, BMTCN® and colleagues created an intervention including an overview of the history of biosimilars and information about the biosimil...